PTO/SB/25 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TERMINAL DISCLAIMER TO OBVIATE A PROVISIONAL DOUBLE PATENTING REJECTION OVER A PENDING "REFERENCE" APPLICATION	O77940.0103
In re Application of: Tony Baker	
Application No.: 09/932,122	
Filed: August 16, 2001	
For: REMOVAL OF MOLECULAR ASSAY INTERFERENCES	
The owner*, Sierra Molecular Corporation, of	11/686,169 filed atent granted on said reference reference application. The owner such period that it and any patent
In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 and 173 of any parapplication, "as the term of any patent granted on said reference application may be shortened by any temperant of any patent on the pending reference application," in the event that: any such patent: granted on the pexpires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent juin whole or terminally disclaimed under 37 CFR 1.321, has all claims canceled by a reexamination certificate terminated prior to the expiration of its full statutory term as shortened by any terminal disclaimer filed prior to	Itent granted on said reference minal disclaimer fled prior to the bending reference application: insdiction, is statutorily disclaimed , is reissued, or is in any manner
Check either box 1 or 2 below, if appropriate.	
1. For submissions on behalf of a business/organization (e.g., corporation, partnership, university, gove etc.), the undersigned is empowered to act on behalf of the business/organization.	rnment agency,
I hereby declare that all statements made herein of my own knowledge are true and that all state belief are believed to be true; and further that these statements were made with the knowledge that willful made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States statements may jeopardize the validity of the application or any patent issued thereon. 2. The undersigned is an attorney or agent of record. Reg. No	false statements and the like so
	26 June 2008 Dete
Signature	Date
Typed or printed name	
	ez6-000L
	2536-0886 Telephone Number
Terminal disclaimer fee under 37 CFR 1.20(d) is included.	
WARNING: Information on this form may become public. Credit card information see included on this form. Provide credit card information and authorization on P	should not TO-2038.
*Statement under 37 CFR 3.73(b) is required if terminal disclaimer is signed by the assignee (owner).	

This collection of information is required by 37 CFR 1.321. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

U.S.Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number STATEMENT UNDER 37 CFR 3.73(b) Applicant/Patent Owner: Sierra Molecular Corporation Application No./Patent No.: 11/686,169 Filed/Issue Date: March 14, 2007 Entitled: Compositions, Systems, And Methods For Preservation And/Or Stabilization Of Macromolecules And/Or Biomolecules Sierra Molecular Corporation , a Corporation (Name of Assignee) (Type of Assignee, e.g., corporation, partnership, university, government agency, etc.) states that it is: 1. It the assignee of the entire right, title, and interest; or 2. \square an assignee of less than the entire right, title and interest. The extent (by, percentage) of its ownership interest is in the patent application/patent identified above by virtue of either: A. [/] An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel 019444, Frame 0520, or for which a copy thereof is attached. OR B. [] A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as shown below: To: The document was recorded in the United States Patent and Trademark Office at Reel ______, Frame______, or for which a copy thereof is attached. To: The document was recorded in the United States Patent and Trademark Office at Reel , Frame , or for which a copy thereof is attached. 3. From: To: The document was recorded in the United States Patent and Trademark Office at or for which a copy thereof is attached. [] Additional documents in the chain of title are listed on a supplemental sheet. [] Copies of assignments or other documents in the chain of title are attached. [NOTE: A separate copy (i.e., the original assignment document or a true copy of the original document) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the USPTO. See MPEP 302.08] The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee. Typed or printed name

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Signature

cto

Coo

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TERMINAL DISCLAIMER TO OBVIATE A PROVISIONAL DOUBLE PATENTING DE JECTION OVED A DENDING "DEEEDENCE" ADDITION

Docket Number (Optional) 077040 0103

RESECTION CALIFACTEDING RELEASED AFFEIGATION	077340.0100	
In re Application of: Tony Baker		
Application No.: 09/932,122		
Filed: August 16, 2001		
For: REMOVAL OF MOLECULAR ASSAY INTERFERENCES		
The owner*, Sierra Molecular Corporation , of 100 percent interest in the instant application hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application which would extend beyond the expiration date of the full statutory term of any patent granted on pending reference Application Number 12/048,961 , filed on March 14, 2008 , as such term is defined in 35 U.S.C. 154 and 173, and as the term of any patent granted on said reference application may be shortened by any terminal disclaimer filed prior to the grant of any patent on the pending reference application. The owner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and any patent granted on the reference application are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns.		
In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 and 173 of any patent granted on said reference application, "as the term of any patent granted on said reference application may be shortened by any terminal disclaimer filed prior to the grant of any patent on the pending reference application," in the event that: any such patent: granted on the pending reference application: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321, has all claims canceled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as shortened by any terminal disclaimer filed prior to its grant.		
Check either box 1 or 2 below, if appropriate.		
1. For submissions on behalf of a business/organization (e.g., corporation, partnership, university, government agency, etc.), the undersigned is empowered to act on behalf of the business/organization.		
I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.		
2. The undersigned is an attorney or agent of record. Reg. No		
	26 June 2008	
Signature	Date	
Typed or printed name		
	09-536-086 Telephone Number	
	relephone Number	
Terminal disclaimer fee under 37 CFR 1.20(d) is included.		
WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.		
*Statement under 37 CFR 3.73(b) is required if terminal disclaimer is signed by the assignee (owner).		

Form PTO/SB/96 may be used for making this statement. See MPEP § 324.

This collection of information is required by 37 CFR 1.321. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 10/31/2002. OMB 0651-0031

U.S.Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

STATEMENT UNDER 37 CFR 3.73(b)		
Applicant/Patent Owner: Sierra Molecular Corporation		
Application No./Patent No.: 12/048,961	Filed/Issue Date: <u>March 14, 2008</u>	
Entitled: COMPOSITIONS, SYSTEMS, AND METHODS FOR PRESERVA	TION AND/OR STABILIZATION OF A CELL AND/OR MACROMOLECULE	
Sierra Molecular Corporation , a Corporation ,		
(Name of Assignee) (Type of As	signee, e.g., corporation, partnership, university, government agency, etc.)	
states that it is:		
1. It the assignee of the entire right, title, and interest;	; or	
2. an assignee of less than the entire right, title and interest. The extent (by, percentage) of its ownership interest is%		
in the patent application/patent identified above by virtu	e of either:	
A. [/] An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel 021075, Frame 0919, or for which a copy thereof is attached.		
OR		
B. [] A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as shown below:		
1. From:		
The document was recorded in the United S Reel, Frame	States Patent and Trademark Office at, or for which a copy thereof is attached.	
2. From:		
	, or for which a copy thereof is attached.	
3. From:T	·o:	
The document was recorded in the United 8	States Patent and Trademark Office at, or for which a copy thereof is attached.	
[] Additional documents in the chain of title are listed on a supplemental sheet.		
[] Copies of assignments or other documents in the chain of title are attached. [NOTE: A separate copy (i.e., the original assignment document or a true copy of the original document) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the USPTO. See MPEP 302.08]		
The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.		
26 July 2008	Tons BAICER	
Date	Typed or printed name	
	Circolous	
	Signature Coo/CTO	
•	Title	

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PTO/SB/25 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

REJECTION OVER A PENDING "REFERENCE" APPLICATION	077940.0103	
In re Application of: Tony Baker		
Application No.: 09/932,122		
Filed: August 16, 2001		
For: REMOVAL OF MOLECULAR ASSAY INTERFERENCES		
The owner', <u>Sierra Molecular Corporation</u> of <u>100</u> percent interest in the instant application hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application which would extend beyond the expiration date of the full statutory term of any patent granted on pending reference Application Number <u>11/774,985</u> filed on <u>July 9, 2007</u> as such term is defined in 35 U.S.C. 154 and 173, and as the term of any patent granted on said reference application may be shortened by any terminal disclaimer filed prior to the grant of any patent on the pending reference application. The owner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and any patent granted on the reference application are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns.		
In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 and 173 of any patent granted on said reference application, "as the term of any patent granted on said reference application may be shortened by any terminal disclaimer filed prior to the grant of any patent on the pending reference application." in the event that: any such patent: granted on the pending reference application: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321, has all claims canceled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as shortened by any terminal disclaimer filed prior to its grant.		
Check either box 1 or 2 below, if appropriate.		
1. For submissions on behalf of a business/organization (e.g., corporation, partnership, university, go etc.), the undersioned is empowered to act on behalf of the business/organization.	vernment agency,	
I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.		
2. The undersigned is an attorney or agent of record. Reg. No		
	26 June 2000	
Signature Salcer Typed or printed name	Date	
long BAICER	The second secon	
Typed or printed name	0 -1 -00/	
	7-536-0896 Telephone Number	
_	reiepnone ivumber	
Terminal disclaimer fee under 37 CFR 1.20(d) is included.		
WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.		
*Statement under 37 CFR 3.73(b) is required if terminal disclaimer is signed by the assignee (owner).		

This collection of information is required by 37 CFR 1.321. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 10/31/2002. OMB 0651-0031

U.S.Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

STATEMENT UNDER 37 CFR 3.73(b)		
Applicant/Patent Owner: Sierra Molecular Corporation		
Application No./Patent No.: 11/774,985	Filed/Issue Date: July 9, 2007	
Entitled: Urine Preservation System		
Sierra Molecular Corporation , a Corporat	ion	
(Name of Assignee) (Type of Ass	ignee, e.g., corporation, partnership, university, government agency, etc.)	
states that it is:		
1. I the assignee of the entire right, title, and interest;	or	
2. an assignee of less than the entire right, title and interest. The extent (by, percentage) of its ownership interest is%		
in the patent application/patent identified above by virtue of either.		
A. [/] An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel 020130, Frame 0718, or for which a copy thereof is attached.		
OR		
B. [] A chain of title from the inventor(s), of the patent assignee as shown below:	application/patent identified above, to the current	
1. From:1	ō:	
The document was recorded in the United S Reel . Frame	States Patent and Trademark Office at, or for which a copy thereof is attached.	
	· · · · · · · · · · · · · · · · · · ·	
The document was recorded in the United S	States Patent and Trademark Office at	
3. From:T	o:	
The document was recorded in the United S	States Patent and Trademark Office at, or for which a copy thereof is attached.	
[] Additional documents in the chain of title are	e listed on a supplemental sheet.	
[] Copies of assignments or other documents in the chain of title are attached. [NOTE: A separate copy (i.e., the original assignment document or a true copy of the original document) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the USPTO. See MPEP 302.08]		
The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.		
26 June 2008	TONU BRICER	
Date	Typed or printed name	
	Signature	
	COO/CTU	
	Title	

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.